Expertise in
7
conditions

Udai Banerji

Fulham Road, 
London, ENG, GB 
Expertise in
7
conditions
Fulham Road, 
London, ENG, GB 

Overview

Udai Banerji practices practicing medicine in London, United Kingdom.

Mr. Banerji is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Ascites, PIK3CA-Related Overgrowth Spectrum, and Lung Cancer.

He is actively involved in clinical research, co-authoring 128 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Fulham Road, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours
FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
A Phase 1, Open-label, Dose-escalation Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 09, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase I Trial of the Combination of PS101-Mediated Acoustic Cluster Therapy (ACT) With Chemotherapy for Treatment of Liver Metastasis In Patients With Solid Tumours With an Expansion Cohort in Metastatic Colorectal And Pancreatic Cancer
Phase I Trial of the Combination of PS101-Mediated Acoustic Cluster Therapy (ACT) With Chemotherapy for Treatment of Liver Metastasis In Patients With Solid Tumours With an Expansion Cohort in Metastatic Colorectal And Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: October 10, 2024
Intervention Type: Drug, Device
Study Phase: Phase 1
TAX-TORC: A Phase I Multi-centre Trial of the Combination of AZD2014 (Dual mTORC1 and mTORC2 Inhibitor) and Weekly Paclitaxel in Patients With Solid Tumours.
TAX-TORC: A Phase I Multi-centre Trial of the Combination of AZD2014 (Dual mTORC1 and mTORC2 Inhibitor) and Weekly Paclitaxel in Patients With Solid Tumours.
Enrollment Status: Completed
Publish Date: September 26, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Cancer Research UK Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody Against Folate Receptor-alpha, in Patients With Advanced Solid Tumours
A Cancer Research UK Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody Against Folate Receptor-alpha, in Patients With Advanced Solid Tumours
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Cancer Research UK Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1) in Patients With Advanced Cancer
A Cancer Research UK Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1) in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: April 11, 2022
Intervention Type: Drug
Study Drug: AZD3965
Study Phase: Phase 1
A Cancer Research UK Phase I First in Man Study of the Novel AGC Kinase Inhibitor AT13148 Given Orally in Patients With Advanced Solid Tumours.
A Cancer Research UK Phase I First in Man Study of the Novel AGC Kinase Inhibitor AT13148 Given Orally in Patients With Advanced Solid Tumours.
Enrollment Status: Completed
Publish Date: July 20, 2018
Intervention Type: Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

128 Total Publications

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026

Frequently Asked Questions about Udai Banerji

Is Udai Banerji a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Udai Banerji is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Udai Banerji participate in research or clinical trials?

Yes. Udai Banerji has published 128 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Udai Banerji's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Banerji's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile